CN111658766A - Application of GSK3 beta and agonist thereof in treatment and rehabilitation of epithelial-derived malignant tumor - Google Patents
Application of GSK3 beta and agonist thereof in treatment and rehabilitation of epithelial-derived malignant tumor Download PDFInfo
- Publication number
- CN111658766A CN111658766A CN202010642170.5A CN202010642170A CN111658766A CN 111658766 A CN111658766 A CN 111658766A CN 202010642170 A CN202010642170 A CN 202010642170A CN 111658766 A CN111658766 A CN 111658766A
- Authority
- CN
- China
- Prior art keywords
- gsk3
- treatment
- tumor
- therapy
- rehabilitation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000001267 GSK3 Human genes 0.000 title claims abstract description 64
- 108060006662 GSK3 Proteins 0.000 title claims abstract description 64
- NFVJNJQRWPQVOA-UHFFFAOYSA-N n-[2-chloro-5-(trifluoromethyl)phenyl]-2-[3-(4-ethyl-5-ethylsulfanyl-1,2,4-triazol-3-yl)piperidin-1-yl]acetamide Chemical compound CCN1C(SCC)=NN=C1C1CN(CC(=O)NC=2C(=CC=C(C=2)C(F)(F)F)Cl)CCC1 NFVJNJQRWPQVOA-UHFFFAOYSA-N 0.000 title claims abstract description 64
- 238000011282 treatment Methods 0.000 title claims abstract description 37
- 201000011510 cancer Diseases 0.000 title claims abstract description 16
- 239000000556 agonist Substances 0.000 title claims abstract description 13
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 54
- 210000004881 tumor cell Anatomy 0.000 claims abstract description 23
- 230000035755 proliferation Effects 0.000 claims abstract description 9
- 230000002147 killing effect Effects 0.000 claims abstract description 6
- 239000003814 drug Substances 0.000 claims description 12
- 238000002560 therapeutic procedure Methods 0.000 claims description 12
- 229940079593 drug Drugs 0.000 claims description 11
- 238000002512 chemotherapy Methods 0.000 claims description 10
- 238000001959 radiotherapy Methods 0.000 claims description 10
- 229940125388 beta agonist Drugs 0.000 claims description 9
- 238000002626 targeted therapy Methods 0.000 claims description 9
- 238000010317 ablation therapy Methods 0.000 claims description 6
- 238000001815 biotherapy Methods 0.000 claims description 6
- 230000008685 targeting Effects 0.000 claims description 6
- 229940126585 therapeutic drug Drugs 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- 230000006907 apoptotic process Effects 0.000 claims description 4
- 230000006269 (delayed) early viral mRNA transcription Effects 0.000 claims description 3
- 239000012190 activator Substances 0.000 claims description 3
- 108091006088 activator proteins Proteins 0.000 claims description 3
- 229940100198 alkylating agent Drugs 0.000 claims description 3
- 239000002168 alkylating agent Substances 0.000 claims description 3
- 239000005557 antagonist Substances 0.000 claims description 3
- 230000000118 anti-neoplastic effect Effects 0.000 claims description 3
- 108091008324 binding proteins Proteins 0.000 claims description 3
- 239000002299 complementary DNA Substances 0.000 claims description 3
- 239000013604 expression vector Substances 0.000 claims description 3
- 229940088597 hormone Drugs 0.000 claims description 3
- 239000005556 hormone Substances 0.000 claims description 3
- 239000003112 inhibitor Substances 0.000 claims description 3
- 230000036210 malignancy Effects 0.000 claims description 3
- 229920001184 polypeptide Polymers 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 239000012268 protein inhibitor Substances 0.000 claims description 3
- 229940121649 protein inhibitor Drugs 0.000 claims description 3
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 230000000340 anti-metabolite Effects 0.000 claims description 2
- 229940088710 antibiotic agent Drugs 0.000 claims description 2
- 229940100197 antimetabolite Drugs 0.000 claims description 2
- 239000002256 antimetabolite Substances 0.000 claims description 2
- 230000002519 immonomodulatory effect Effects 0.000 claims description 2
- 229940124622 immune-modulator drug Drugs 0.000 claims description 2
- 238000011277 treatment modality Methods 0.000 claims 2
- 230000003612 virological effect Effects 0.000 claims 2
- 102000014914 Carrier Proteins Human genes 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 108091006086 inhibitor proteins Proteins 0.000 claims 1
- 230000001035 methylating effect Effects 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 230000004083 survival effect Effects 0.000 abstract description 8
- 206010027476 Metastases Diseases 0.000 abstract description 7
- 230000009401 metastasis Effects 0.000 abstract description 7
- 230000000259 anti-tumor effect Effects 0.000 abstract description 6
- 238000000034 method Methods 0.000 abstract description 5
- 230000006909 anti-apoptosis Effects 0.000 abstract description 4
- 230000004069 differentiation Effects 0.000 abstract description 3
- 230000004060 metabolic process Effects 0.000 abstract description 3
- 230000003213 activating effect Effects 0.000 abstract description 2
- 230000012010 growth Effects 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 7
- 238000009169 immunotherapy Methods 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 230000003044 adaptive effect Effects 0.000 description 4
- 229940044683 chemotherapy drug Drugs 0.000 description 4
- 230000007705 epithelial mesenchymal transition Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 2
- 241000027355 Ferocactus setispinus Species 0.000 description 2
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 2
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 2
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 description 2
- 102100038104 Glycogen synthase kinase-3 beta Human genes 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 102000023732 binding proteins Human genes 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000009087 cell motility Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000019522 cellular metabolic process Effects 0.000 description 2
- 229940079919 digestives enzyme preparation Drugs 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 2
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- 102000015790 Asparaginase Human genes 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 102000008096 B7-H1 Antigen Human genes 0.000 description 1
- 108010074708 B7-H1 Antigen Proteins 0.000 description 1
- 102000015735 Beta-catenin Human genes 0.000 description 1
- 108060000903 Beta-catenin Proteins 0.000 description 1
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102100030011 Endoribonuclease Human genes 0.000 description 1
- 101710199605 Endoribonuclease Proteins 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 241000237858 Gastropoda Species 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000038030 PI3Ks Human genes 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 101710113029 Serine/threonine-protein kinase Proteins 0.000 description 1
- 241001116500 Taxus Species 0.000 description 1
- PDMMFKSKQVNJMI-BLQWBTBKSA-N Testosterone propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CC)[C@@]1(C)CC2 PDMMFKSKQVNJMI-BLQWBTBKSA-N 0.000 description 1
- 102000007501 Thymosin Human genes 0.000 description 1
- 108010046075 Thymosin Proteins 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
- 229960003437 aminoglutethimide Drugs 0.000 description 1
- 230000003527 anti-angiogenesis Effects 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 239000003972 antineoplastic antibiotic Substances 0.000 description 1
- 229940045985 antineoplastic platinum compound Drugs 0.000 description 1
- 229960003272 asparaginase Drugs 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 108700004675 bleomycetin Proteins 0.000 description 1
- QYOAUOAXCQAEMW-UTXKDXHTSA-N bleomycin A5 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCCNCCCCN)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C QYOAUOAXCQAEMW-UTXKDXHTSA-N 0.000 description 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
- 229960001467 bortezomib Drugs 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- YAYRGNWWLMLWJE-UHFFFAOYSA-L carboplatin Chemical compound O=C1O[Pt](N)(N)OC(=O)C11CCC1 YAYRGNWWLMLWJE-UHFFFAOYSA-L 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- -1 cell factor Proteins 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 238000011254 conventional chemotherapy Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 229960003603 decitabine Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
- 229960000452 diethylstilbestrol Drugs 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
- 229960003881 letrozole Drugs 0.000 description 1
- 229960001786 megestrol Drugs 0.000 description 1
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 210000004738 parenchymal cell Anatomy 0.000 description 1
- 150000003058 platinum compounds Chemical class 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000009682 proliferation pathway Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 229960001712 testosterone propionate Drugs 0.000 description 1
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 241001446247 uncultured actinomycete Species 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 229960004355 vindesine Drugs 0.000 description 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/11—Protein-serine/threonine kinases (2.7.11)
- C12Y207/11013—Protein kinase C (2.7.11.13)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The invention discloses an application of GSK3 beta and an agonist thereof in the treatment and rehabilitation of epithelial malignant tumors, which can reduce the anti-apoptosis threshold level of tumor cells, interfere the proliferation and metabolism process of the tumor cells, slow down the growth speed of the tumors, promote the differentiation of the tumor cells and reduce the recurrence of the tumors by activating GSK3 beta, can improve the killing effect of various existing tumor treatment methods on the tumors by reducing the overall anti-apoptosis level of the tumors and up-regulate the overall anti-tumor capability of organisms, promote the rehabilitation of patients, and is one of the most fundamental means for improving the overall anti-tumor capability of the tumor patients, improving the survival time and the survival quality of the patients and reducing the recurrence and metastasis of the tumors.
Description
Technical Field
The invention relates to the technical field of clinical tumor treatment, in particular to application of GSK3 beta and an agonist thereof in treatment and rehabilitation of epithelial-derived malignant tumor.
Background
The recurrence and metastasis of malignant tumors are the most problematic problems faced by clinical tumor therapy. Surgery, chemotherapy and radiotherapy are currently the most common means of tumor treatment.
The operation treatment is the first choice treatment means for most of early and middle stage tumors in clinic, and can play a radical treatment effect on part of early stage tumors which are not subjected to distant metastasis, while the early stage metastasis problem of the tumors becomes an important factor for restricting the operation effect on middle and late stage tumors and part of early stage tumors with high malignancy degree. Chemotherapy is a systemic treatment that works on both primary and metastatic tumors. The chemotherapy drugs can be used alone, or several chemotherapy drugs can be combined or sequentially used, or combined with other treatment means such as surgery, radiotherapy and the like. Conventional chemotherapy aims to suppress proliferation of tumor cells and promote death of tumor cells. The chemotherapy of regular and pedicure course can effectively eliminate the tumor cells which are sensitive to the chemotherapy in part of tumor patients. However, increasing the dose of the chemotherapeutic drug or prolonging the chemotherapeutic time for insensitive (such as cell proliferation cycle G0, tumor cells in partial G1 stage, and tumor stem cells) or resistant tumor cells does not allow the patient to benefit further, and the toxic and side effects of the chemotherapeutic drug are gradually increased. Radiotherapy has a good killing effect on part of radiotherapy-sensitive tumor cells, particularly proliferation cells, but the radiation characteristic of radiotherapy determines that the radiotherapy is mainly adopted in a local treatment mode, and the radical removal of tumors is difficult to achieve in principle by the radiotherapy with a tolerant dose, so that the recurrence of the tumors cannot be avoided under most conditions.
In recent years, new therapeutic means such as targeted therapy and immunotherapy are being applied to clinical application, and new hopes are brought to tumor treatment. The targeting and immunotherapy are mainly applied to patients with corresponding gene mutation or high expression of immune related markers, and the treatment effect of part of patients is obvious. However, the cost of targeting and immunotherapy is high and the highly heterogeneous tumor tissue is also constantly placing changing demands on targeted drugs or immunotherapy. The drug resistance of tumor tissues to targeting or immunotherapy is improved due to continuous adaptive mutation of tumors under the same target, and the proliferation progress of heterogeneous tumor subgroups with different genotypes or epigenotypes needs to be continuously developed and applied aiming at different related abnormal proliferation targets or immune targets. Clinical studies with targeted therapy and immunotherapy have shown that for most of the enrolled cases, targeted and immunotherapy under the current conditions does not completely prevent the recurrence of the tumor.
The method searches a new target for treating the malignant tumor, improves the treatment effect of the malignant tumor, prolongs the overall survival time of a tumor patient, and is an urgent subject in the field of tumor research.
Among the many targets for tumor research, glycogen synthase Kinase-3 β (glycogen synthase Kinase-3 β, GSK3 β) is receiving increasing attention from researchers. GSK3 β is a highly conserved serine/threonine protein kinase widely present in almost all eukaryotes, and was originally discovered as a regulator of glycogen metabolism. Numerous studies have been conducted to confirm whether GSK3 β is also a downstream critical regulation switch for various signal pathways. These pathways include: RAS/MAPK/ERK, P38MAPK, JNK, PI3K/AKT, Wnt/beta-Catenin, PKC, PKA, NF-kB, Receptor Tyrosine Kinases (RTK), Notch, Hedgehog, G protein-coupled receptors (GPCR) and other signal pathways. GSK3 β participates in a wide range of signaling cascades, involving cell metabolism, cell cycle regulation, proliferation, differentiation, motility, substance transport, biorhythm control, apoptosis, etc.
GSK3 β was also found to be involved in the metastatic process of tumor cells. Epithelial-mesenchymal Transition (EMT) is considered to be a key element in the development of metastasis of tumor cells. The tumor cells with EMT transformation are transformed from epithelial cell characteristics to mesenchymal cell characteristics, and the enhancement of cell movement and migration capacity is accompanied, so that a foundation is provided for invasion and metastasis of tumors. GSK3 β plays an important role in EMT by modulating Wnt, Hedgehog and Snail pathways.
The effects of GSK3 β include: GSK3 β is a key regulatory node for cell death, cell differentiation or proliferation, and is one of the most central substances for healthy survival and function development around parenchymal cells during the evolution of a living body. The GSK3 beta can play its role in regulating cell metabolism direction, regulating the switch of cell survival adaptive pathway, regulating biological rhythm, regulating cell movement and substance transport. GSK3 β is also a precise regulator in the dose-response system of living organisms, plays a central role in regulation in the processes of channel selection, opening degree of different channels, channel compensation, etc., and is also the most important determinant of adaptive capacity of tissue cells.
GSK3 β also plays an extremely important role in the development and progression of tumor cells. Inhibition of GSK3 β activity is a prerequisite for activation of multiple proliferation pathways, anti-apoptosis and adaptive survival of tumor cells. In view of the important role of GSK3 β in tumor development and progression, tumor therapy targeting GSK3 β is expected to be high.
Disclosure of Invention
In view of the above situation, the present invention provides a GSK3 β and its agonist for use in the treatment and rehabilitation of epithelial malignant tumors by activating GSK3 β to reduce the anti-apoptotic threshold level of tumor cells, interfere with the proliferative metabolic process of tumor cells, slow down the growth rate of tumors, promote the differentiation of tumor cells, and reduce the recurrence of tumors.
In order to achieve the purpose, the invention adopts the following technical scheme:
GSK3 beta and application of an agonist thereof in treatment and rehabilitation of epithelial-derived malignant tumors, wherein the application utilizes the GSK3 beta or GSK3 beta agonist to promote apoptosis of tumor cells, slow proliferation of the tumor cells, and enhance killing effect on the tumors by combining with conventional tumor treatment means.
Further, the GSK3 beta comprises virus or non-virus expression vector of artificially synthesized GSK3 beta protein or active polypeptide, GSK3 beta complete gene sequence, cDNA or ORF, and the GSK3 beta agonist comprises GSK3 beta active binding protein, GSK3 beta activator protein and activator thereof, and inhibitor or antagonist of GSK3 beta inhibitory protein.
Further, the conventional tumor treatment means includes chemotherapy, radiotherapy, targeted therapy, interventional therapy, cold/heat ablation therapy, biological therapy.
Further, the GSK3 β or GSK3 β agonist is used prior to, during or after administration of a chemotherapy, targeted therapy, interventional therapy, cold/heat ablation therapy, biological therapy session.
Further, the main therapeutic drugs used in the therapeutic means include, but are not limited to, alkylating agents, hormones, antimetabolites, antibiotics, antitumor plants, platins, protein inhibitors, enzyme preparations, methylation drugs, antitumor targeting drugs, monoclonal antibodies for tumor therapy, immunomodulatory and therapeutic drugs.
Has the advantages that:
the application of GSK3 beta and the agonist thereof in the treatment and rehabilitation of epithelial malignant tumors provided by the invention has the following beneficial effects:
the GSK3 beta and GSK3 beta agonists are used in the treatment scheme of the epithelial malignant tumor, can improve the killing effect of various existing tumor treatment methods on the tumor and promote the recovery of a patient by reducing the integral anti-apoptosis level of the tumor and increasing the integral anti-tumor capability of an organism, and is one of the most fundamental means for improving the integral anti-tumor capability of the tumor patient, improving and improving the survival time and the survival quality of the patient and reducing the tumor recurrence and metastasis.
Drawings
FIG. 1 is a flow chart of the treatment of the present invention.
Detailed Description
The invention is further described below with reference to the accompanying drawings.
The GSK3 beta and the application of the agonist thereof in the treatment and rehabilitation of epithelial-derived malignant tumors provided by the invention utilize GSK3 beta or GSK3 beta agonists to promote the apoptosis of tumor cells and slow down the proliferation of the tumor cells, and the killing effect on tumors is enhanced by combining with conventional tumor treatment means.
The GSK3 beta comprises virus or non-virus expression vector of artificially synthesized GSK3 beta protein or active polypeptide, GSK3 beta complete gene sequence, cDNA or ORF, and the GSK3 beta excitant comprises GSK3 beta active binding protein, GSK3 beta activator protein and activator thereof, and inhibitor or antagonist of GSK3 beta inhibitory protein.
The conventional tumor treatment means comprises chemotherapy, radiotherapy, targeted therapy, intervention therapy, cold/heat ablation therapy and biological therapy, and the GSK3 beta or GSK3 beta agonist is used before, during or after the chemotherapy, the targeted therapy, the intervention therapy, the cold/heat ablation therapy and the biological therapy. The tumor treatment means can be used singly or in combination of several means or sequentially.
The main therapeutic drugs used in the treatment means include but are not limited to alkylating agents used for tumor therapy (such as cyclophosphamide, ifosfamide, chlorambucil, carmustine, melphalan, malignane, etc.); metabolites (e.g., methotrexate, cytarabine, fludarabine, gemcitabine, fluorouracil, hydroxyurea, etc.); antineoplastic antibiotics (including adriamycin, daunorubicin, pingyangmycin, actinomycete D, doxorubicin and epirubicin); antineoplastic plant medicine (such as vinblastine (vincristine, vindesine), homotricuspid ester, and taxus); hormones (e.g., prednisone, dexamethasone, diethylstilbestrol, megestrol, testosterone propionate, tamoxifen, aminoglutethimide, letrozole, flutamide, etc.); platinum compounds (such as cisplatin, carboplatin, oxaliplatin, etc.); enzyme preparations (e.g., asparaginase); protein inhibitor drugs (such as bortezomib); methylated drugs (e.g., decitabine, azacitidine); targeted therapeutic drugs (such as anti-angiogenesis drugs and tyrosine kinase inhibitors); drugs of monoclonal antibodies (e.g., rituximab, herceptin, etc.) for tumor therapy; immune regulation and treatment (such as thymosin, interferon, cell factor, PD-1 monoclonal antibody, PD-L1 monoclonal antibody, CTLA-4 monoclonal antibody), the drug treatment comprises single drug administration or combination of several drugs or sequential drug administration of several drugs.
The limitation of the protection scope of the present invention is understood by those skilled in the art, and various modifications or changes which can be made by those skilled in the art without inventive efforts based on the technical solution of the present invention are still within the protection scope of the present invention.
Claims (5)
- The application of GSK3 beta and an agonist thereof in the treatment and rehabilitation of epithelial-derived malignant tumors is characterized in that the GSK3 beta or GSK3 beta agonist is used for promoting the apoptosis of tumor cells and slowing the proliferation of the tumor cells, and the killing effect on the tumors is enhanced by combining with a conventional tumor treatment means.
- 2. The use of GSK3 β and agonists thereof for the treatment and rehabilitation of epithelial-derived malignancies as claimed in claim 1, wherein GSK3 β comprises a viral or non-viral expression vector artificially synthesized to GSK3 β protein or active polypeptide, GSK3 β complete gene sequence, cDNA or ORF, and the GSK3 β agonists include GSK3 β active binding proteins, GSK3 β activator proteins and activators thereof, inhibitors or antagonists of GSK3 β inhibitor proteins.
- 3. The use of GSK3 β and agonists thereof in the treatment and rehabilitation of malignant tumors of epithelial origin as claimed in claim 1, wherein said conventional tumor treatment modalities include chemotherapy, radiation therapy, targeted therapy, interventional therapy, cold/heat ablation therapy, biological therapy.
- 4. The use of GSK3 β and agonists thereof for the treatment and rehabilitation of malignancies of epithelial origin as claimed in claims 2 or 3, wherein the GSK3 β or GSK3 β agonists are used before, during or after the course of chemotherapy, targeted therapy, interventional therapy, cold/heat ablation therapy, biological therapy.
- 5. The use of GSK3 β and agonists thereof for the treatment and rehabilitation of malignant tumors of epithelial origin according to claim 4, wherein the main therapeutic drugs used in said treatment modalities include, but are not limited to, alkylating agents, hormones, antimetabolites, antibiotics, antineoplastic plants, platins, protein inhibitors, enzymes, methylating agents, antineoplastic targeting drugs, monoclonal antibodies for tumor therapy, immunomodulating and therapeutic drugs.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010642170.5A CN111658766A (en) | 2020-07-06 | 2020-07-06 | Application of GSK3 beta and agonist thereof in treatment and rehabilitation of epithelial-derived malignant tumor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010642170.5A CN111658766A (en) | 2020-07-06 | 2020-07-06 | Application of GSK3 beta and agonist thereof in treatment and rehabilitation of epithelial-derived malignant tumor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111658766A true CN111658766A (en) | 2020-09-15 |
Family
ID=72391429
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010642170.5A Pending CN111658766A (en) | 2020-07-06 | 2020-07-06 | Application of GSK3 beta and agonist thereof in treatment and rehabilitation of epithelial-derived malignant tumor |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111658766A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1980681A (en) * | 2004-07-09 | 2007-06-13 | 新加坡科技研究局 | Modulation of GSK-3beta and method of treating proliferative disorders |
| US20110150887A1 (en) * | 2008-04-30 | 2011-06-23 | University Of Vermont And State Agricultural College | Methods and products relating to gsk3beta regulation |
| CN106794175A (en) * | 2014-06-12 | 2017-05-31 | 西达-赛奈医疗中心 | For the composition and method for the treatment of cancer |
-
2020
- 2020-07-06 CN CN202010642170.5A patent/CN111658766A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1980681A (en) * | 2004-07-09 | 2007-06-13 | 新加坡科技研究局 | Modulation of GSK-3beta and method of treating proliferative disorders |
| US20110150887A1 (en) * | 2008-04-30 | 2011-06-23 | University Of Vermont And State Agricultural College | Methods and products relating to gsk3beta regulation |
| CN106794175A (en) * | 2014-06-12 | 2017-05-31 | 西达-赛奈医疗中心 | For the composition and method for the treatment of cancer |
Non-Patent Citations (3)
| Title |
|---|
| 杨娇等: "糖原合成酶激酶-3β对不同类型肿瘤作用机制", 《医药导报》 * |
| 郭昊等: "肿瘤治疗关键靶点糖原合成酶激酶-3β的研究进展", 《广东化工》 * |
| 马竹君等: "GSK-3β、E-cadherin、Cytokeratin在口腔鳞状细胞癌中的表达及意义", 《贵州医药》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Liu et al. | Metabolic reprogramming and therapeutic resistance in primary and metastatic breast cancer | |
| Lin et al. | The roles of glucose metabolic reprogramming in chemo-and radio-resistance | |
| Lévi et al. | Implications of circadian clocks for the rhythmic delivery of cancer therapeutics | |
| Ganapathy-Kanniappan et al. | Tumor glycolysis as a target for cancer therapy: progress and prospects | |
| Lu et al. | The molecular basis of targeting PFKFB3 as a therapeutic strategy against cancer | |
| Fels et al. | The PERK/eIF2α/ATF4 module of the UPR in hypoxia resistance and tumor growth | |
| Fang et al. | Roles of glucose transporter-1 and the phosphatidylinositol 3‑kinase/protein kinase B pathway in cancer radioresistance | |
| Teuwen et al. | Endothelial cell metabolism: an update anno 2017 | |
| Jeong et al. | Intravesical instillation of c-MYC inhibitor KSI-3716 suppresses orthotopic bladder tumor growth | |
| Ždralević et al. | Metabolic plasiticy in cancers—distinct role of glycolytic enzymes GPI, LDHs or membrane transporters MCTs | |
| Gu et al. | Impact of lactate on immune cell function in the tumor microenvironment: Mechanisms and therapeutic perspectives | |
| Marchetti et al. | Integration of mitochondrial targeting for molecular cancer therapeutics | |
| Zhang et al. | Research progress on therapeutic targeting of quiescent cancer cells | |
| Zuzčák et al. | Cellular metabolism in pancreatic cancer as a tool for prognosis and treatment | |
| Liu et al. | Lactate: a rising star in tumors and inflammation | |
| US20070281040A1 (en) | Combination therapy of hedgehog inhibitors, radiation and chemotherapeutic agents | |
| Lee et al. | Hypoxia-inducible factor-1α and excision repair cross-complementing 1 in patients with small cell lung cancer who received front-line platinum-based chemotherapy: a retrospective study | |
| Derle et al. | The role of metabolic adaptation to nutrient stress in pancreatic cancer | |
| Liu et al. | Ginsenoside Rh2 shifts tumor metabolism from aerobic glycolysis to oxidative phosphorylation through regulating the HIF1-α/PDK4 axis in non-small cell lung cancer | |
| Farsani et al. | Lactate mediated metabolic crosstalk between cancer and immune cells and its therapeutic implications | |
| Beilankouhi et al. | Role of the ER-induced UPR pathway, apoptosis, and autophagy in colorectal cancer | |
| Lv et al. | Long noncoding RNAs: glycolysis regulators in gynaecologic cancers | |
| El-Demiry et al. | Necroptosis modulation by cisplatin and sunitinib in hepatocellular carcinoma cell line | |
| Wang et al. | AURKB enhances chromosomal remodeling of telomeric genes and accelerates tumorigenesis of uveal melanoma | |
| CN111658766A (en) | Application of GSK3 beta and agonist thereof in treatment and rehabilitation of epithelial-derived malignant tumor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200915 |
|
| RJ01 | Rejection of invention patent application after publication |